Welcome to our dedicated page for Tyra Biosciences news (Ticker: TYRA), a resource for investors and traders seeking the latest updates and insights on Tyra Biosciences stock.
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company based in Carlsbad, CA, focused on developing next-generation precision medicines that target significant opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The Company leverages its proprietary precision medicine platform, SNÅP, to enable rapid and precise drug design through iterative molecular SNÅPshots that predict genetic alterations likely to cause acquired resistance to existing therapies.
Tyra’s lead product candidate, TYRA-300, is an investigational oral FGFR3-selective inhibitor aimed at treating cancer and skeletal dysplasias, including achondroplasia. TYRA-300 is currently being evaluated in a multi-center, open-label Phase 1/2 clinical study, SURF301 (Study in Untreated and Resistant FGFR3+ Advanced Solid Tumors). SURF301 is designed to determine the optimal and maximal tolerated doses (MTD) and the recommended Phase 2 dose (RP2D) of TYRA-300, as well as to evaluate its preliminary antitumor activity. TYRA-300 has demonstrated positive preclinical results in skeletal dysplasias, and Tyra expects to submit an Investigational New Drug (IND) application to the FDA for a Phase 2 clinical study in pediatric achondroplasia in 2024.
Another key product in development is TYRA-200, an investigational oral FGFR1/2/3 inhibitor with potency against activating FGFR2 gene alterations and resistance mutations for the treatment of cancer. TYRA-200 is currently undergoing evaluation in a multi-center, open-label Phase 1 clinical study, SURF201 (Study in Previously treated and Resistant FGFR2+ Cholangiocarcinoma and Other Advanced Solid Tumors). SURF201 is designed to determine the optimal and MTD and RP2D of TYRA-200 and to evaluate its preliminary antitumor activity.
Tyra has recently achieved significant milestones, including the FDA granting Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) Designation to TYRA-300 for treating achondroplasia. The Company is also actively presenting research findings at major scientific congresses such as the American Society for Bone and Mineral Research (ASBMR) and the American Society of Human Genetics (ASHG).
In 2024, Tyra secured approximately $200 million in funding via a securities purchase agreement with institutional and accredited investors, led by RA Capital Management. This financial boost strengthens Tyra's balance sheet as the company advances its clinical development programs and leverages the SNÅP platform for discovering new drug candidates.
Tyra Biosciences' vision is to provide novel therapeutic options for patients with unmet medical needs by developing best-in-class precision medicines. Their ongoing research, clinical trials, and financial stability position them well to achieve this goal.
Tyra Biosciences (Nasdaq: TYRA), a clinical-stage biotechnology firm, announced its participation in key investor conferences. CEO Todd Harris will engage in a fireside chat at Cantor's The Future of Oncology Virtual Symposium on April 4, 2023, at 2:15 PM ET. He will also present at the Bank of America 2023 Healthcare Conference on May 11, 2023, at 9:35 AM PT. TYRA focuses on developing precision medicines targeting FGFR biology and utilizes its innovative SNÅP platform for drug design. For live updates and webcasts, visit the company's investor page.
Tyra Biosciences (TYRA) reported financial results for 2022 and highlighted key milestones. The company initiated patient dosing for TYRA-300 in the SURF301 oncology study and expanded its pipeline to treat achondroplasia. The FDA cleared the IND for TYRA-200's Phase 1 study, expected to begin in 2H 2023. For 2022, TYRA recorded a full-year net loss of $55.3 million, compared to $26.3 million in 2021. R&D expenses increased to $43 million, and the company maintains a strong cash position with $251.2 million available, ensuring over two years of runway for its development plans.
FAQ
What is the current stock price of Tyra Biosciences (TYRA)?
What is the market cap of Tyra Biosciences (TYRA)?
What is Tyra Biosciences' core focus?
What is TYRA-300?
What is the SNÅP platform?
What are the current clinical trials for TYRA-300?
What designations has TYRA-300 received?
What is TYRA-200?
What recent funding did Tyra Biosciences secure?
Who are the key people in Tyra Biosciences?
Where is Tyra Biosciences located?
How can I learn more about Tyra Biosciences?
